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Summary
Ataxia-telangiectasia (A-T) is an autosomal recessive
disorder characterized by cerebellar degeneration, im-
munodeficiency, chromosomal instability, radiosensitiv-
ity, and cancer predisposition. A-T cells are sensitive to
ionizing radiation and radiomimetic chemicals and fail
to activate cell-cycle checkpoints after treatment with
these agents. The responsible gene, ATM, encodes a
large protein kinase with a phosphatidylinositol 3-ki-
nase–like domain. The typical A-T phenotype is caused,
in most cases, by null ATM alleles that truncate or se-
verely destabilize the ATM protein. Rare patients with
milder manifestations of the clinical or cellular charac-
teristics of the disease have been reported and have been
designated “A-T variants.” A special variant form of A-
T is A-TFresno, which combines a typical A-T phenotype
with microcephaly and mental retardation. The possible
association of these syndromes with ATM is both im-
portant for understanding their molecular basis and es-
sential for counseling and diagnostic purposes.We quan-
tified ATM-protein levels in six A-T variants, and we
searched their ATM genes for mutations. Cell lines from
these patients exhibited considerable variability in ra-
diosensitivity while showing the typical radioresistant
DNA synthesis of A-T cells. Unlike classical A-T pa-
tients, these patients exhibited 1%–17% of the normal
level of ATM. The underlying ATM genotypes were ei-
ther homozygous for mutations expected to produce
mild phenotypes or compound heterozygotes for a mild
and a severe mutation. An A-TFresno cell line was found
devoid of the ATM protein and homozygous for a severe
ATMmutation. We conclude that certain “A-T variant”
phenotypes represent ATM mutations, including some
of those without telangiectasia. Our findings extend the
range of phenotypes associated with ATM mutations.
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Introduction
Ataxia-telangiectasia (A-T; MIM 208900) is a complex,
multisystem disorder inherited in an autosomal recessive
manner. The major manifestations of A-T are progres-
sive cerebellar degeneration leading to severe neuro-
motor dysfunction, oculocutaneous telangiectasia, pro-
found immunodeficiency of both humoral and cellular
compartments, gonadal dysgenesis, growth retardation
in some patients, high levels of serum alpha-fetoprotein,
predisposition to malignancies (primarily lymphoreti-
cular), and acute radiosensitivity. A-T cells show chro-
mosomal instability, premature senescence, accelerated
telomere shortening, sensitivity to the cytotoxic and clas-
togenic effects of ionizing radiation and radiomimetic
chemicals, and defective activation of cell-cycle check-
points by these agents (Sedgwick and Boder 1991; Shiloh
1995, 1997; Gatti 1996; Lavin and Shiloh 1997).
The responsible gene, ATM, has been mapped to chro-
mosome 11q22-23 (Gatti et al. 1988; Lange et al. 1995)
and subsequently has been identified by use of a posi-
tional cloning approach (Savitsky et al. 1995a, 1995b;
GenBank accession numbers U67092 and U67093 [http:
//www.ncbi.nlm.nih.gov/]). This gene occupies 150 kb
of genomic DNA structured into 66 exons that encode
a 13-kb transcript (Savitsky et al. 1995b, 1997; Uziel et
al. 1996). The ATM protein is a large, 370-kD phos-
phoprotein localized mainly in the nucleus (Chen and
Lee 1996; Lakin et al. 1996; Brown et al. 1997; Watters
et al. 1997). ATM is a member of a family of proteins,
identified in various organisms, that share a carboxy-
terminal region similar to the catalytic subunit of phos-
phatidylinositol 3-kinases (PI 3-kinases). These proteins
are involved in cellular responses to DNA damage, and
some of them play regulatory roles in cell-cycle pro-
gression or damage-induced cell-cycle checkpoints. Mu-
tations in some of the corresponding genes lead to ge-
nomic instability and sensitivity to DNA damaging
agents (reviewed by Savitsky et al. 1995b; Jorgensen and
Shiloh 1996;Shiloh and Rotman 1996 Hoekstra 1997;
Lavin and Shiloh 1997;). Evidence is accumulating that
ATM indeed plays an important role in several signal-
transduction pathways associated with stress responses
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or normal cellular growth (Hoekstra 1997; Khanna et
al. 1997; Rotman and Shiloh, in press).
Extensive screening of the ATM gene or transcript in
A-T patients has revealed a large variety of mutations,
most of which are unique to single families. The great
majority of these mutations are expected to completely
inactivate the ATM protein, mostly by truncations. The
A-T phenotype is thus determined by homozygosity or
compound heterozygosity for ATM null alleles (Baumer
et al. 1996; Byrd et al. 1996; Gilad et al. 1996a, 1996b,
and in press; Telatar et al. 1996; Vorechovsky et al.
1996; Wright et al. 1996; Concannon and Gatti, in
press).
Despite some variability in several features of the dis-
ease, patients with the classical A-T phenotype usually
have been grouped together and have not been subdi-
vided into clinical subtypes. This approach has been ret-
rospectively supported by the uniform nature of ATM
mutations underlying classical A-T, which did not lead
to the establishment of genotype-phenotype relation-
ships within this group. Occasionally, however, milder
cases of the disease—“A-T variants”—have been re-
ported. Such patients may show either later age at onset
or more-moderate severity of the ataxia, intermediate
cellular radiosensitivity, and longer life span than is seen
in most A-T patients (Stankler and Bennett 1973; Ying
and Docteau 1981; Fiorilli et al. 1984; Taylor et al. 1987,
1993; de Jong and Tijssen 1988; Maserati et al. 1988;
Ziv et al. 1989; Chessa et al. 1992; Lanzi et al. 1992;
Sanal et al. 1993; Willems et al. 1993; Antoccia et al.
1995).
In addition to variants exhibiting milder forms of A-
T, other syndromes have been reported that include some
A-T signs combined with other clinical features (re-
viewed by Taylor et al. [1993] and Bundey [1994]).Most
notable is the Nijmegen breakage syndrome (NBS),
which combines chromosomal instability, cancer predis-
position, and the typical A-T cellular phenotype with
microcephaly and, sometimes, mental retardation (Wee-
maes et al. 1994; Wegner et al., in press). NBS patients
do not show ataxia or telangiectasia, and the responsible
gene is separate from ATM (Stumm et al. 1995; Gatti
1996; Saar et al. 1997). Curry et al. (1989) identified in
identical twin girls a rare combination of the classical
A-T phenotype with microcephaly and mental retarda-
tion; they designated this syndrome “ATFresno.” This syn-
drome segregates with 11q22-23 markers (Gatti 1996).
We have attempted to determinewhether this phenotypic
variation correlates with ATM mutations and levels of
ATM protein expression. The clinical and cellular char-
acteristics, ATM protein levels, and underlying ATM
mutations were examined in a series of mild A-T vari-
ants, and a search for ATM mutations was performed
on a cell line derived from one of the ATFresno sisters.
Material and Methods
Cell Lines
Lymphoblastoid cell lines (LCLs) were established
from peripheral blood lymphocytes of patients, as de-
scribed elsewhere (Littlefield et al. 1981). The normal
lymphoblast line GM02184 was obtained from the Na-
tional Institute of General Medical Sciences’ Human
Mutant Cell Repository (Corriell Institute for Medical
Research, Camden, NJ). Lymphoblasts were grown in
RPMI 1640 medium, and fibroblasts were grown in Dul-
becco’s modified Eagle’s medium, each supplemented
with 15% fetal bovine serum (Beit Ha‘Emek Biological
Industries and Gibco BRL).
Cellular Sensitivity to Ionizing Radiation
LCLs were seeded at a density of 2 # 105 cells/ml;
were irradiated with various doses of gamma rays, by
use of a J.L. Shepherd Mark I cesium-137 irradiator;
and were returned to the incubator. Cell density was
measured daily for 7 d after irradiation, and cell growth
was assessed relative to an unirradiated culture, for each
cell line. Relative cell growth was plotted as a function
of treatment dose, and a sensitivity score was calculated
for each patient’s cell line, on the basis of the ratio be-
tween the dose leading to 50% growth inhibition in that
cell line and the dose leading to 50% growth inhibition
in control cells.
Radioresistant DNA Synthesis (RDS)
The cells were prelabeled with [2-14C]thymidine and
were irradiated with various doses of gamma rays (for
experimental details, see Ziv et al. 1995). The rate of
DNA synthesis after irradiation was quantified by mea-
suring the incorporation of tritiated thymidine into chro-
mosomal DNA during 1 h, beginning 1 h after
irradiation.
Western Blotting Analysis of the ATM Protein
Cellular extracts were fractionated by PAGE and were
transferred to nitrocellulose membranes, as described by
Gilad et al. (1996a) and Ziv et al. (1997). The ATM
protein was detected with a polyclonal antiserum
(X2361) raised against a recombinant protein spanning
amino acids 2361–2547 of the ATM protein. An anti-
actin antibody (Sigma) was used to quantitate variations
in protein amounts loaded in different lanes. Immuno-
reactive bands were visualized by use of the Super Signal
system (Pierce), and the signals were quantitated by den-
sitometry using the BioImaging Densitometry system
202D (Dinco and Renium).
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Table 1
Phenotypic Characterization of Six A-T Variants
Clinical/Laboratory Feature AT53RM AT9RMa AT31RMb A(-T)2RMbc AT42RM AT35RM
Age (years) 12 20 38 22 33 31
Sex F F F F M F
Telangiectasia      
Age at onset of ataxia
(years)
9 4 2 2 1.5 4
Choreoathetosis      
Ocular apraxia      
Nystagmus      
Recurrent infections      
Immunodeficiency    c  
Increased alpha-fetoprotein      
Malignancy      
Chromosomal instability   NTd   
Clonal translocations   NTd   
a This patient and her affected sister have been described in detail by Chessa et al. (1992) and Antoccia et
al. (1995).
b NT  not tested.
c For detailed phenotypic description, see the work of Maserati et al. (1988) and Lanzi et al. (1992).
d Reduced IgE and normal IgA.
Search for ATM Mutations
The ATM transcript was screened for mutations by
use of reverse transcriptase–PCR (RT-PCR) followed by
restriction-endonuclease fingerprinting. Suspect regions
of the ATM transcript were sequenced to identify specific
mutations. This protocol has recently been described in
detail by Gilad et al. (1998).
Results
Definition of the Variant Phenotype
There is no uniform definition of the A-T variant phe-
notype. Six mild A-T variants examined in this study
manifested most or all of the hallmarks of the A-T phe-
notype, but each one deviated from classical A-T in at
least one phenotypic feature (table 1); This deviation
could be either a later age at onset and slower progres-
sion of the neurological signs of the disease (patient
AT53RM), reduced radiosensitivity (patient AT9RM
[Chessa et al. 1992]), absence of telangiectasia (patient
A[-T]2RM), or longer life span (patients AT31RM,
AT42RM, and AT35RM). All these patients are Italian.
Cellular Responses to Ionizing Radiation
Two of the hallmarks of the A-T cellular phenotype
are increased sensitivity to the cytotoxic effect of ionizing
radiation and reduced inhibition of semiconservative
DNA synthesis after radiation treatment (reviewed by
Thacker [1994] and Shiloh [1995]). The latter phenom-
enon, termed “radioresistant DNA synthesis” (RDS)
(Houldsworth and Lavin 1980; Painter and Young
1980), represents a defect in the induction of an S-phase
checkpoint by radiation damage.
The common assay of cellular survival after treatment
with DNA-damaging agents measures clonogenic
growth of the cells. In view of the difficulty in the ap-
plication of this assay to newly established LCLs, their
radiosensitivity was assessed by means of a growth-in-
hibition assay. Ionizing radiation inhibited cellular
growth in the cell lines of all six patients, to a greater
extent than it did in the control cell line, although the
response was variable. In their postirradiation growth
pattern, some of the patients’ cell lines resembled typical
A-T cells, whereas others showed higher or lower sen-
sitivities (fig. 1 and table 2). Variable extents of RDS
were also observed, ranging from above to below the
values for the typical A-T cell lines (fig. 2 and table 2).
RDS and radiosensitivity were not correlated, but the
small sample size does not allow statistically significant
analysis.
ATM-Protein Level
Western blot analysis and densitometry were used to
assess the levels of ATM protein in the cell lines. The
readings of the ATM signals were normalized against
the actin readings (fig. 3). Whereas two classical A-T
cells typically showed no immunoreactive signal with an
ATM antiserum, the variant cell lines exhibited variable
levels of the ATM protein, in the range of ∼1%–17%
of the normal level (fig. 3 and table 2). Notably, there
was no apparent correlation between ATM-protein lev-
els and the two parameters of the cellular pheno-
type—radiosensitivity and RDS (table 2).
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Figure 1 Radiation survival of LCLs, as measured by relative
growth at 72 h (A) and 96 h (B) postirradiation, in a control
(GM02184 [ ]), in classical A-T (AT65RM [ ] and L-3 []), and
in A-T variants (AT53RM [], AT42RM [], AT9RM [], AT35RM
[], AT31RM [], and A[-T]2RM []).
ATM Mutations
The variable levels of ATM protein in the variant cell
lines indicated ATM mutations. A search for mutations
in these cell lines revealed several ATM defects that had
not previously been found in patients with classical A-
T (table 3).
The truncating mutation 9139CrT at codon 3047,
identified in patient AT9RM, shortens the large ATM
protein by just 10 amino acids. To date, this is the small-
est extent of truncation noted among ATM mutant al-
leles. The truncated protein is clearly less stable than the
normal protein (fig. 3 and table 2), and its biochemical
activity may be reduced, since the catalytic domain of
the protein is expected to be in the carboxy-terminal PI
3-kinase–like region (Brown et al. 1995).
The splicing mutation 3576GrA seems to be a leaky
mutation that leaves a residual amount of normally
spliced ATM transcript. The mutation leads to a base
substitution at the last position of exon 26, which results
in a defective but not completely abolished splice site
(fig. 4) (Mount 1982; Maquat 1996). In both patients
homozygous for this mutation—patents AT31RM and
A(-T)2RM—the cellular amount of ATMprotein is∼5%
of the normal level, probably reflecting both the amount
of full-length ATM transcript produced by this allele and
the stability of its protein product (fig. 4). It is important
to note, however, that the two patients homozygous for
the same mutation differ in a central feature of the A-
T phenotype—that is, the appearance of telangiectasia.
The 3576GrA mutation appears also in two other A-
T variants—patients AT42RM and AT35RM—each of
whom is a compound heterozygote for this mutation and
another, unknown mutation. Heterozygosity for the
3576GrA mutation was revealed by sequencing ge-
nomic PCR products spanning the mutation site. RT-
PCR followed by sequence analysis of the corresponding
region in the ATM transcript failed, however, to detect,
in either patient, the transcript of the other ATM allele.
This may be due to mutation(s) that either preclude the
expression of those alleles or severely destabilize their
RNA products. Both patients therefore demonstrate the
outcome of compound heterozygosity for a null allele
and a milder, leaky mutation.
The 3576GrA mutation thus appears in four Italian
families, pointing to a founder effect. Patients AT31RM
and A(-T)2RM live in two villages located 35 km apart
in central Italy, whereas patients AT35RM and
AT42RM come from two adjacent villages in southern
Italy.
Patient AT53RM is a compound heterozygote exhib-
iting a relatively high level of the ATM protein (∼12%
of the normal level). The IVS47-9GrA mutation in one
of this patient’s ATM alleles activates a cryptic splice
site within intron 47 and, a priori, could be leaky. The
amino acid substitution and amino acid deletion caused
by the second mutation, 5435del3, probably destabilize
the ATM protein. On the basis of this patient alone, it
is hard to determine the relative share of each mutation
in the residual amount of protein found in the patient’s
cells. However, a clue to the outcome of the IVS47-
9GrA mutation was obtained when this mutation was
identified in a classical A-T patient, AT65RM, who is a
second cousin of patient AT53RM (fig. 5). In this pa-
tient, the other allele contains a typical truncation mu-
tation. Since the classical A-T phenotype is determined
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Table 2
Radiation Response and ATM-Protein Level in Classical and Variant A-T Cell lines
Patient Group
Radiation-Dose Ratio
Yielding 50% Growth
at 72 ha
Thymidine-Incorpora-
tion Ratio at 25 Gyb
ATM-Protein Level
(%c)
Classical A-T:
L-3d .62 1.55 0
AT65RM .49 1.39 0
A-T variants:
AT9RM .47 1.92 16.8
AT31RM .66 2.05 4.8
A(-T)2RM .55 1.68 5.4
AT42RM .47 1.74 1.0
AT35RM .55 2.16 1.0
AT53RM .66 1.69 11.7
a The ratio between the doses required for inhibition of cellular growth by 50%, in this
cell line and in normal cells.
b The ratio between thymidine incorporation following treatment with 25 Gy in this cell
line and that in normal cells.
c Of normal protein level.
d Moroccan-Jewish A-T patient homozygous for a stop codon mutation at position 35 of
the ATM protein (Gilad et al. 1996a).
Figure 2 RDS in LCLs: relative nucleotide incorporation, with
increasing radiation dose, for a normal control (GM02184 []), in
classical A-T (L-3 []), and in A-T variants (AT35RM [] and
A[-T]2RM []).
by null alleles (Gilad et al. 1996b), and because
AT65RM cells do not produce any ATM protein (fig.
3), it became apparent that the IVS47-9GrA mutation
is probably not leaky and in fact represents a null allele.
This leaves the entire amount of the ATM protein in
patient AT53RM to be produced by the 5435de13 allele.
The family depicted in figure 5 therefore represents an
example of segregation of three ATM mutations in one
family, two with severe A-T mutations and one with a
milder mutation that leaves a fraction of the ATM pro-
tein probably with some residual activity.
An ATM Mutation in an A-TFresno Patient
The fibroblast cell line AT25LA derived from one of
the A-TFresno sisters is as radiosensitive as a typical A-T
cell line (Curry et al. 1989). No immunoreactivematerial
was identified in this cell line by use of an anti-ATM
antibody (not shown). Screening the ATM transcript in
this cell line revealed homozygosity for a typical A-T
mutation, which abolished a splice site at intron 33 of
the ATM gene and led to skipping of exon 32 (table 3).
The resultant large deletion in the protein probably se-
verely destabilizes the ATM molecule. This result estab-
lishes that the A-T component in the phenotype of the
twin sisters described by Curry et al. (1989) is indeed
caused by an ATM mutation of the type that usually
leads to classical A-T.
Discussion
There is no universally accepted definition of the
A-T variant phenotype. The considerable variability of
many of the clinical features of A-T sometimes makes
it difficult to distinguish between classical and variant
patients (Taylor et al. 1993; Bundey 1994). This dis-
tinction is often retrospective, particularly when the pa-
tient reaches an advanced age or exhibits slow progres-
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Figure 3 Western blotting analysis of cellular extracts prepared
from various LCLs. The same blot was reacted with antibodies against
ATM (top panel) and actin (bottom panel) (seeMaterial andMethods).
Equal amounts of protein were loaded in the lanes representing pa-
tients, and 10% of that amount was loaded in the control lane (lane
L-39). Variable amounts of the ATM protein are observable in A-T
variants, whereas no ATM can be detected in two classical patients
(lanes AT24RM and AT65RM).
sion of the disease. Sometimes the clinical phenotype is
typical of A-T patients but the cellular phenotype is less
severe. The definition of patients as variants may there-
fore be subjective. However, it is important to identify
atypical phenotypes that are allelic to A-T, since the lo-
calization of the responsible mutation within the ATM
gene provides a reliable basis for genetic counseling, car-
rier detection within the affected family, and prenatal
diagnosis. One quick way to establish the connection
between a possible A-T–variant phenotype and the ATM
gene is western blotting analysis of the ATM-protein
level. A significantly reduced level would indicate in-
volvement of the ATM gene.
The A-T–variant patients described in this study were
defined as such on the basis of an overall picture of their
disease, which usually displayed a milder form of at least
one of the disease features. It should be noted that none
of these patients suffers from recurrent sinopulmonary
infections, which characterize 50%–60% of classical A-
T patients. It is well established, however, that, even
among classical patients, there is no correlation between
the degree of immune deficiency and the appearance of
recurrent infections (Roifman and Gelfand 1985). Pre-
viously reported variants typically did not exhibit this
characteristic.
One of the A-T features that consistently appears in
the variants, including those without telangiectasia, is
chromosomal instability, often with the typical clonal
translocations involving the sites of the immune-system
genes (for examples, see the work of Ying and Docteau
[1981] and Maserati et al. [1988]); this is the case with
the variants described here as well. In view of the ex-
tended life span of these patients, compared with typical
A-T cases, it is reasonable to assume that they are less
cancer prone than are classical A-T patients. Thus, this
phenotype might reflect a possible dissociation between
the chromosomal instability and predisposition to lym-
phoid malignancies in A-T.
Although telangiectasia is regarded as an essential fea-
ture for the diagnosis of A-T (Sedgwick and Boder
1991), this is one of the most variable features of the
A-T phenotype (Bundey 1994; Sanal et al. 1993; Taylor
et al. 1993). Clinicians may not consider cerebellar
ataxia as a possible representation of A-T unless it is
accompanied by telangiectasia. Several cases with clin-
ical and cellular characteristics of A-T but without tel-
angiectasia have been reported (Ying and Docteau 1981;
Byrne et al. 1984; Taylor et al. 1987; Maserati et al.
1988; Stell et al. 1989; Lanzi et al. 1992; Willems et al.
1993; de Graaf et al. 1994). In the present study, patient
A(-T)2RM presents an important example of a pheno-
type that is caused by an ATM mutation but that does
not include telangiectasia. Friedman and Weitberg
(1993) proposed a new umbrella category of “ataxia
with immune deficiency.” Patients with this double com-
bination often also present chromosomal instability and
other A-T cellular features (see references cited above).
In view of these considerations and our finding of an
ATM mutation in patient A(-T)2RM, we propose that
A-T features such as chromosomal instability, immu-
nodeficiency, and high serum alpha-fetoprotein levels be
searched for in patients with sporadic or unclassified
cerebellar ataxias. If an “A-T–like” phenotype is found,
a search for an ATM mutation would be appropriate.
A-T variants have also been defined by testing their
cellular phenotype. In this study we investigated two
hallmarks of this phenotype—radiosensitivity and RDS.
Both features have been studied extensively in fibroblast
and LCLs from A-T patients. LCLs are immortalized,
but they faithfully retain the cellular A-T features ob-
served in primary fibroblast lines—including radiosen-
sitivity, RDS, and defective activation of the G1/S and
G2/M cell-cycle checkpoints by ionizing radiation (for
examples, see Houldsworth and Lavin 1980; Beamish
and Lavin 1984; Beamish et al. 1996). Even the inter-
mediate radiosensitivity of A-T heterozygotes is clearly
observed in cellular-survival assays applied to lympho-
blasts (Chen et al. 1978). It should also be noted that
the LCLs in our experiments were at relatively low pas-
sage levels. Although the growth inhibition used in the
present study may be less sensitive to subtle differences
in radiosensitivity, which can be detected by clonogenic
growth of fibroblasts, results strikingly similar to ours
recently have been reported in a study of fibroblast lines
from a series of British A-T variants: a wide range of
radiosensitivity was observed, with no correlation with
the severity of the clinical phenotype (Taylor 1997).
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Table 3
ATM Mutations Identified in Patients
Patient Group Transcript Mutationa Genomic Mutationb
Predicted Protein
Alteration Genotype
A-T variants:
AT9RM 9139CrT Base substitution in
exon 65
Argrter; truncation at
codon 3047
Homozygosity
AT31RM 3403del174 3576GrA In-frame deletion of 58
amino acids at codon
1135
Homozygosity
A(-T)2RM 3403del174 3576GrA In-frame deletion of 58
amino acids at codon
1135
Homozygosity
AT42RM 3403del174 3576GrA In-frame deletion of 58
amino acids at codon
1135
Compound
heterozygosityc
amino acids at codon
1135
AT35RM 3403del174 3576GrA In-frame deletion of 58
amino acids at codon
1135
Compound
heterozygosityc
AT53RM 6572ins7 IVS47-9GrA Truncation at codon
2198
Compound
heterozygosity
AT53RM 5435del3 3-bp deletion in exon
38
A1812V and in-frame
deletion of 1813Phe
Compound
heterozygosity
Classical A-T:
AT65RM 8814del11 11-bp deletion in exon
63
Truncation at codon
2951
Compound
heterozygosity
AT65RM 6572ins7 IVS47-9GrA Truncation at codon
2198
Compound
heterozygosity
ATFresno:
AT25LA 4612del165 IVS332TrC In-frame deletion of 55
amino acids at codon
1538
Homozygosity
a Presented according to the nomenclature proposed byAntonarakis et al. and the Nomenclature Working Group (1998); the first
nucleotide of the ATM open reading frame was designated “1” (GenBank accession number U33841[http://www.ncbi.nlm.nih.gov/]).
b Exon numbers are according to Uziel et al. (1996).
c The other ATM allele is not expressed.
We also noted, in the patients’ cell lines, a lack of
correlation between the degree of cellular radiosensitiv-
ity and RDS. The sample size did not allow us to draw
significant statistical conclusions, but it should be noted
that the two phenomena are not necessarily correlated
and can be dissociated from each other by certain ma-
nipulations (reviewed by Jorgensen and Shiloh 1996;
Lavin and Shiloh 1997).
A-T patients with radiosensitivity that is reduced com-
pared with that in classical patients have been reported.
Interestingly, postirradiation DNA synthesis in such pa-
tients could be either normal, similar to that in classical
patients, or intermediate (Fiorilli et al. 1984; Taylor et
al. 1987). Patient AT9RM, studied here, showed a fairly
typical clinical phenotype but, because of both (a) in-
termediate radiosensitivity of her lymphocytes (Chessa
et al. 1986) and fibroblasts (Chessa et al. 1992) and (b)
normal postirradiation DNA synthesis observed in her
fibroblasts (Chessa et al. 1992), was classified as a var-
iant. Antoccia et al. (1995) noted nearly normal post-
irradiation DNA synthesis in the LCL established from
this patient. In our hands, however, this LCL shows both
radiosensitivity in the A-T range and RDS typical for A-
T cell lines. This cell line was characterized by a dynamic
clonal evolution, indicated by the spread of a
t(2;14)(p12;q32) translocation (Chessa et al. 1989), and
this may also have contributed to its current phenotype,
which resembles that of classical A-T cells. These results
underscore differences in such parameters, between cell
lines and between laboratories, particularly when the
parameters are measured across extended time periods,
and they call for caution when they are used to evaluate
a patient’s phenotype. Indeed, Chessa et al. (1992) and
Antoccia et al. (1995) stressed the lack of correlation
between the severity of the clinical phenotype in A-T
and the degree of both radiosensitivity and RDS ob-
served in patients’ cell lines.
Patients A(-T)2RMandAT31RMare homozygous for
the same ATM mutation, yet they differ phenotypically
in a cardinal feature of A-T—the telangiectasia. This
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Figure 4 Consequences of the leaky splicing mutation 3576GrA
observation points to the involvement of other physio-
logical factors in the determination of the extent—and
even existence—of the disease features. The mutation
common to these patients is leaky, allowing expression
of the ATM protein at ∼5% of its normal level. Another
leaky ATM mutation was found in compound heter-
ozygosity with severe mutations in a group of British A-
T variants. That mutation caused activation of a cryptic
splice site within the ATM gene (McConville et al. 1996).
A severe defect in the same splice site, affected by the
3576GrA mutation, has been identified in a Turkish A-
T patient, F-2095, in whom one of the ATM alleles
contains a IVS261delG mutation (Gilad et al. 1996b).
That mutation, which eliminates the GT consensus dinu-
cleotide at the beginning of intron 26, abolishes this
splice site completely and leads to an ATM null allele.
Patients AT42RM and AT35RM were classified as
variants primarily because of their longer life span, com-
pared with that for typical A-T patients. A-T variants
who reached the ages of 44 and 58 years were reported
by de Jonge and Tijssen (1988) and Ying and Docteau
(1981). The latter authors assumed that their patient
represented an allelic form of classical A-T. In view of
our findings, this is highly likely. Patients AT42RM and
AT35RM are compound heterozygotes for the
3576GrA mutation and a null allele that is not ex-
pressed. In that respect, they are similar to the British
A-T variants reported by McConville et al. (1996), who
are compound heterozygotes for severe and leaky ATM
mutations. It is of interest that the phenotype of patients
AT42RM and AT35RM resembles that of patient
AT31RM, who is homozygous for the 3576GrA mu-
tation. In many autosomal recessive disorders, the in-
teraction between severe and mild mutations gives rise
to clinical variability (for examples, see the work of
Gravel et al. [1995] and Guttler and Guldberg [1996]).
Patient AT9RM shows the highest ATM-protein level
in this series. Had this level been determined by a reg-
ulatory mutation, and had the protein itself not been
altered, the resulting phenotype would be expected to
be relatively mild. This patient’s mutation led, however,
to a minute truncation of the protein, which was prob-
ably responsible for reduction in both its catalytic ac-
tivity and stability, reductions that, together, led to a
rather pronounced phenotype. This mutation highlights
the importance of the carboxy-terminal domain of the
ATM protein, which probably harbors the catalytic site
of this protein kinase.
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Figure 5 Segregation of three ATM mutations in two families
A-TFresno (Curry et al. 1989) represents a typical A-T
phenotype with additional features. A distinction should
be made between such syndromes and A-T variants who
have milder forms of the classical disease but who have
no additional signs. The typical A-T mutation identified
in the A-TFresno cell line indicates, however, that the A-T
component in this phenotype is caused by an ATM mu-
tation of the type that characterizes classical A-T,
whereas the microcephaly and mental retardation rep-
resent a different genetic or environmental etiology.
The mutations identified in this study in A-T variants
affect the ATM-protein function and level less severely
than do the null mutations typical of classical A-T. Nev-
ertheless, even these mutations leave only residual active
protein. The mutations found in A-T patients and in A-
T variants may still represent only a portion of the ATM
defects in the population. ATM mutations of a more
minor nature must underlie various other phenotypes,
making far from complete the known spectrum of ge-
notype-phenotype combinations associated with this
gene.
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